Amyris, Inc. (AMRS)

Biotechnology company focused on renewable products, including sustainable alternatives to petroleum-based ingredients.

AMRS Stock Quote

Company Report

Amyris, Inc. Logo Amyris, Inc., headquartered in Emeryville, California, is a leading synthetic biotechnology company with a strong presence in the clean health and beauty, as well as flavors and fragrance markets across Europe, North America, Asia, and South America. Established in 2003 as Amyris Biotechnologies, Inc., the company rebranded to Amyris, Inc. in June 2010. Amyris manufactures and markets a diverse range of products including clean beauty, personal care, health and wellness consumer goods, and ingredients for the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care sectors.

Under various brand names such as Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN, Amyris offers innovative solutions that cater to evolving consumer preferences for sustainable and bio-based products. The company's proprietary technology platform enables the production of high-performance ingredients that are sustainably sourced and manufactured, aligning with global initiatives towards environmental conservation and ethical sourcing practices.

In addition to its commercial endeavors, Amyris collaborates with renowned organizations like the Infectious Disease Research Institute to develop solutions addressing global health challenges, such as the development of a COVID-19 vaccine. This partnership underscores Amyris's commitment to leveraging its biotechnology expertise for impactful contributions in healthcare innovation. With a dedication to sustainability and cutting-edge biotechnology, Amyris continues to pioneer advancements in the fields of clean beauty, personal care, and sustainable ingredients, driving positive change in global markets.

AMRS EPS Chart

AMRS Revenue Chart

Stock Research

GNE LSXMA ASCB MSEX SAIA CRMD ROCK

AMRS Chart

View interactive chart for AMRS

AMRS Profile

AMRS News

Analyst Ratings